



PEER-REVIEW REPORT

Name of journal: World Journal of Meta-Analysis

Manuscript NO: 66359

Title: Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide 1 receptor agonists: A systematic review

Reviewer's code: 03674832

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Greece

Author's Country/Territory: South Africa

Manuscript submission date: 2021-03-27

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-27 08:03

Reviewer performed review: 2021-03-27 09:04

Review time: 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) <input checked="" type="checkbox"/> Minor revision [] Major revision [] Rejection
Re-review	<input checked="" type="checkbox"/> Yes [] No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Evaluation of the Systemic Review paper 66359 entitled “Glycated Haemoglobin Reduction and Fixed Ratio Combinations of Analogue Basal Insulin and Glucagon-Like Peptide 1 Receptor Agonists- A Systematic Review”. The aim of this systemic review was to describe and contrast the glycated haemoglobin reduction of two fixed ratio combinations of analogue basal insulin and glucagon like peptide-1 receptor agonist in adults with type 2 diabetes mellitus (T2DM). The authors suggest that both iGlarLixi and IDegLira effectively reduce glycated haemoglobin. Indirect comparisons, using insulin glargine as the common comparator, suggest that IDegLira reduces glycated haemoglobin to a greater extent than iGlarLixi. However, given the limitations of indirect comparisons, robust head to head studies and real-world data would better inform clinician choice and clinical practice guidelines. Comments for the authors

1. This paper is a well written paper on an interesting and useful issue.
2. The text and the tables are appropriate and informative.
3. The references are up to date, but the following might improve the paper: -Mannucci E, Naletto L, Vaccaro G, Silverii A, Dicembrini I, Pintaudi B, Monami M. Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials. *Nutr Metab Cardiovasc Dis.* 2021 Apr 9;31(4):1027-1034. -Rayner CK, Wu T, Aroda VR, Whittington C, Kanters S, Guyot P, Shaunik A, Horowitz M. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis. *Diabetes Obes Metab.* 2021 Jan;23(1):136-146 -Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? *Diabetes Metab Res Rev.* 2019 Jan;35(1):e3070.
4. There are practical implications of the results of the paper for



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

T2DM patients.



PEER-REVIEW REPORT

Name of journal: World Journal of Meta-Analysis

Manuscript NO: 66359

Title: Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide 1 receptor agonists: A systematic review

Reviewer's code: 03674017

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: China

Author's Country/Territory: South Africa

Manuscript submission date: 2021-03-27

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-27 07:32

Reviewer performed review: 2021-03-29 04:25

Review time: 1 Day and 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input checked="" type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This systematic review investigated the glucose-lowering efficacy of IGLarLixi and IDegLira in treating people with diabetes. Nevertheless, it provides very limited information to academia and is far from well prepared. The eligibility of the study is more likely a trial rather than a systematic review. It added very limited information to the 2017 publication. It considers only the change of HbA1c making this study limited to conclude what the author wrote in the paper.



PEER-REVIEW REPORT

Name of journal: World Journal of Meta-Analysis

Manuscript NO: 66359

Title: Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide 1 receptor agonists: A systematic review

Reviewer’s code: 05418714

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: South Africa

Manuscript submission date: 2021-03-27

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-07 14:06

Reviewer performed review: 2021-04-07 14:26

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input checked="" type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The manuscript is less innovative, and the research design is not sufficient, so the manuscript cannot be published.



PEER-REVIEW REPORT

Name of journal: World Journal of Meta-Analysis

Manuscript NO: 66359

Title: Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide 1 receptor agonists: A systematic review

Reviewer's code: 05866045

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Oman

Author's Country/Territory: South Africa

Manuscript submission date: 2021-03-27

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-30 02:38

Reviewer performed review: 2021-04-12 19:27

Review time: 13 Days and 16 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[] Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Dear author, Your work was really excellent. It was filled all the checklist criteria. Further, the work, knowledge and information you was writing in your research was amazing.